[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371140-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371140-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","male-breast-cancer-common-biomarkers-clinicopathology-and-outcomes-in-the-west-of-iran","Male breast cancer - common biomarkers, clinicopathology, and outcomes in the west of Iran","","Male breast cancer is a rare condition accounting for under 1% of cancers in men and diagnosed breast cancers, and its clinical evidence remains limited. A descriptive cross-sectional retrospective evaluation analyzed clinicopathologic features, treatment patterns, metastatic behavior, immunohistochemical markers, and survival in male cases across a 10-year period (2012–2021). Older age, higher stage, and presence of metastasis were linked to poorer overall survival, with significant associations found among age, metastasis, stage, and survival status.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/male-breast-cancer-common-biomarkers-clinicopathology-and-outcomes-in-the-west-of-iran/371140/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/male-breast-cancer-common-biomarkers-clinicopathology-and-outcomes-in-the-west-of-iran/371140.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study design and time period for evaluating male breast cancer outcomes?","Question",{"text":63,"@type":64},"The study used a descriptive cross-sectional design and retrospectively evaluated male breast cancer cases over 10 years, from 2012 to 2021.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which clinicopathologic factors were found to be associated with unfavorable survival?",{"text":68,"@type":64},"The findings associated older age, higher disease stage, and metastasis with unfavorable overall survival.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key results regarding tumor type, metastasis frequency, and survival rates?",{"text":72,"@type":64},"Invasive ductal carcinoma was diagnosed in 86.3% of patients; metastasis occurred in 23.5%, commonly to the liver and then the bone marrow. Overall survival at 1, 3, and 5 years was reported as 96%, 91%, and 65%, respectively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371140,1790927465,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":106,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Azizi et al.  \nJournal of the Egyptian National Cancer Institute (2025) 37:35  \n[https://doi.org/10.1186/s43046-025-00294-y](https://doi.org/10.1186/s43046-025-00294-y)  \nJournal of the Egyptian National Cancer Institute  \n RESEARCH Open Access  \nMale breast cancer: common biomarkers, clinicopathology, and outcomes in the west of Iran  \nAli Azizi1*, Nasrin Mansouri 1, Bayan Faridi 1 and Mazaher Ramezani1  \nAbstract  \nBackground Male breast cancer is a rare disease that accounts for less than 1% of all cancers in men and less than 1% of all diagnosed breast cancers. We retrospectively evaluated clinicopathologic features, treatment options, and overall survival in male breast cancer cases over 10 years (2012–2021) .  \nMethods In this descriptive-cross-sectional study, the men with a breast cancer patient information based on demographic characteristics, type of surgery performed, pathological characteristics of samples (including the typeof tumor involving lymph nodes and its grade), distant metastasis, immunohistochemical markers as well as family history of cancer, number of chemotherapy and radiotherapy sessions, use of anabolic drugs, and patient survival after surgery were recorded in the designed checklist.  \nResults The results showed that the mean age of men with breast cancer was 56.14 ± 14.59. Invasive ductal carcinoma was diagnosed in 86. 3% of patients. In addition, metastasis occurred in 23. 5% of patients, and most metastases occurred in the liver and then in the bone marrow, respectively. The highest frequency was related to stage IIB, with a frequency of 29 .4% . The overall survival rate of 1, 3, and 5 years for 51 cases was 96%, 91%, and 65%, respectively, with an average survival period of 96 months. There was a significant relationship between age, metastasis, and disease stage with the survival status of patients (P = 0 . 03) .  \nConclusions In the present study, old age, higher stage, and metastasis in male breast cancer were associated with unfavorable survival.  \nKeywords Male, Breast cancer, Prognostic factors, Survival  \nIntroduction  \nBreast cancer in males currently represents 0.5% of all cancer diagnoses among men annually and constitutes approximately 1% of all breast cancer cases in the USA [1]. Despite its rarity, the incidence of male breast cancer is increasing [2].  \nMen diagnosed with breast cancer have historically been underrepresented in clinical trials and  \n*Correspondence: Ali Azizi [aliazizi@kums.ac.ir](aliazizi@kums.ac.ir)  \n1 Kermanshah University of Medical Sciences, Kermanshah, Islamic Republic of Iran  \npopulation-based research, primarily due to the rarity of the condition. Currently, there are no reported outcomes from prospective national or international clinical studies that focus exclusively on male breast cancer patients. Given the limited availability of male-specific data, clinicians must rely on findings from studies that primarily involve female breast cancer patients to inform disease management strategies. Consequently, the treatment protocols for male breast cancer patients are largely analogous to those employed for postmenopausal women [3].  \nWhile breast cancer constitutes a relatively small proportion of all malignancies diagnosed in males, it is associated with one of the highest mortality rates. According to the American Cancer Society, in 2019, the incidence of  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creativ","cbCaicZPNxXK6mB5","https://ap.wps.com/l/cbCaicZPNxXK6mB5","pdf",1232342,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# License and publication notes","[{\"question\":\"What was the study design and time period for evaluating male breast cancer outcomes?\",\"answer\":\"The study used a descriptive cross-sectional design and retrospectively evaluated male breast cancer cases over 10 years, from 2012 to 2021.\"},{\"question\":\"Which clinicopathologic factors were found to be associated with unfavorable survival?\",\"answer\":\"The findings associated older age, higher disease stage, and metastasis with unfavorable overall survival.\"},{\"question\":\"What were the key results regarding tumor type, metastasis frequency, and survival rates?\",\"answer\":\"Invasive ductal carcinoma was diagnosed in 86.3% of patients; metastasis occurred in 23.5%, commonly to the liver and then the bone marrow. Overall survival at 1, 3, and 5 years was reported as 96%, 91%, and 65%, respectively.\"}]","Male breast cancer - common biomarkers, clinicopathology, and outcomes in the west of Iran | PDF",1790191338,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51ad91d2610db74e42092688bcb63052.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37ef8c14027504bdea1672c64adcbf8f.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d74f5a1f05b7fce6088c0c12661084e5.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/739fe9b61927e212f63264dfc34aac89.webp",980,1301]